COLESTIPOL HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for COLESTIPOL HYDROCHLORIDE (COLESTIPOL HYDROCHLORIDE).
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation and increasing hepatic conversion of cholesterol to bile acids, lowering serum LDL cholesterol.
| Metabolism | Not metabolized; not absorbed systemically. |
| Excretion | Colestipol hydrochloride is not absorbed systemically; it is excreted entirely in the feces as the intact polymer, without undergoing metabolism. No renal or biliary elimination occurs. |
| Half-life | Not applicable as colestipol is not absorbed; it acts locally in the gastrointestinal tract and has no systemic half-life. |
| Protein binding | Not applicable; the drug is not absorbed and does not bind to plasma proteins. |
| Volume of Distribution | Not applicable; colestipol is not absorbed and remains within the gastrointestinal lumen. |
| Bioavailability | 0% for systemic absorption; it is non-absorbable and acts locally in the intestine. |
| Onset of Action | 1-2 weeks for reduction in serum total and LDL cholesterol levels after oral administration. |
| Duration of Action | Duration persists for 24 hours with daily dosing; maximal effect may require 1 month of therapy. |
Initial: 5 g orally once daily or 2.5 g twice daily; increase gradually by 5 g/day at 1-2 month intervals; maintenance: 5-30 g/day divided once or twice daily; maximum: 30 g/day.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment recommended; use with caution in severe renal impairment due to potential for hyperchloremic metabolic acidosis. |
| Liver impairment | No specific dose adjustment recommended; caution in severe hepatic impairment due to possible decreased cholesterol synthesis. |
| Pediatric use | Not established for children <10 years; for ≥10 years, initial: 5 g orally once daily; increase gradually to 5-20 g/day divided once or twice daily. |
| Geriatric use | No specific dose adjustment; monitor for gastrointestinal adverse effects and potential interactions with other medications due to altered GI motility and polypharmacy. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for COLESTIPOL HYDROCHLORIDE (COLESTIPOL HYDROCHLORIDE).
| Breastfeeding | Colestipol is not absorbed systemically and not excreted into breast milk. Compatible with breastfeeding. M/P ratio not applicable. |
| Teratogenic Risk | Colestipol hydrochloride is not absorbed systemically, thus no direct fetal exposure. No teratogenic risk expected. First trimester: minimal risk. Second/third trimester: no known adverse fetal effects. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to colestipol hydrochloride or any component","Complete biliary obstruction","Phenylketonuria (if formulation contains aspartame)"]
| Precautions | ["May cause hypertriglyceridemia","Risk of vitamin K deficiency and bleeding (due to bile acid binding)","May impair absorption of fat-soluble vitamins (A, D, E, K)","May cause constipation or fecal impaction (especially in elderly)","May interfere with absorption of other drugs (e.g., warfarin, thyroid hormones, digoxin); separate administration by at least 1 hour or as specified"] |
Loading safety data…
| Monitor maternal lipid profiles, coagulation parameters (prothrombin time) due to potential vitamin K deficiency, and maternal nutritional status. Assess fetal growth if prolonged use. |
| Fertility Effects | No known effects on fertility. Theoretical interference with fat-soluble vitamin absorption does not impact fertility. |